实时监测药物-检验交互:一项概念验证研究
该研究在荷兰三家医院实施电子临床决策支持系统(CDSS),通过43条临床规则实时监测药物-检验交互(DLTI)。每院每天约触发65条DLTI警报,最常见为钾-质子泵抑制剂(16%)、钾-β受体阻滞剂(11%)和肌酸激酶-他汀类(11%),表明实时警报可行。
要点
- CDSS可实时监测药物-检验交互并触发警报。
- 每院每天约65条DLTI警报,多来自内科和ICU。
- 最常见交互为钾-质子泵抑制剂、钾-β受体阻滞剂和肌酸激酶-他汀类。
核心结论
- CDSS可在三家医院成功实施并实时触发潜在DLTI警报。
- 需进一步研究揭示其在临床实践中的实用性。
研究设计与样本
- 多中心概念验证研究,在荷兰三家医院实施CDSS。
- 基于荷兰临床化学与实验室医学学会DLTI数据库选择交互,编程43条临床规则,涵盖24项检验和25种药物。
- 为期一个月,所有生成的DLTI警报登记在实验室信息系统中。
主要发现
- 每院每天检测到约65条DLTI警报。
- 多数DLTI警报来自内科和重症监护病房患者。
- 最常见DLTI警报为钾-质子泵抑制剂(16%)、钾-β受体阻滞剂(11%)和肌酸激酶-他汀类(11%)。
关键数值与推荐
- 临床规则基于检验结果超出参考范围并结合处方药物触发警报。
临床怎么用
- CDSS可随检验结果实时提示潜在DLTI,辅助临床正确解读检验结果。
局限性
- 研究仅为期一个月,未评估对临床结局的影响。
- 需进一步研究揭示其在临床实践中的实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: For the correct interpretation of test results, it is important to be aware of drug-laboratory test interactions (DLTIs). If DLTIs are not taken into account by clinicians, erroneous interpretation of test results may lead to a delayed or incorrect diagnosis, unnecessary diagnostic testing or therapy with possible harm for patients. A DLTI alert accompanying a laboratory test result could be a solution. The aim of this study was to test a multicentre proof of concept of an electronic clinical decision support system (CDSS) for real-time monitoring of DLTIs. METHODS: CDSS was implemented in three Dutch hospitals. So-called 'clinical rules' were programmed to alert medical specialists for possible DLTIs based on laboratory test results outside the reference range in combination with prescribed drugs. A selection of interactions from the DLTI database of the Dutch society of clinical chemistry and laboratory medicine were integrated in 43 clinical rules, including 24 tests and 25 drugs. During the period of one month all generated DTLI alerts were registered in the laboratory information system. RESULTS: Approximately 65 DLTI alerts per day were detected in each hospital. Most DLTI alerts were generated in patients from the internal medicine and intensive care departments. The most frequently reported DLTI alerts were potassium-proton pump inhibitors (16%), potassium-beta blockers (11%) and creatine kinase-statins (11%). CONCLUSIONS: This study shows that it is possible to alert for potential DLTIs in real-time with a CDSS. The CDSS was successfully implemented in three hospitals. Further research must reveal its usefulness in clinical practice.
引用
- van Balveren JA, Verboeket-van de Venne WPHG, Doggen CJM, et al. Real-time monitoring of drug laboratory test interactions: a proof of concept. Clin Chem Lab Med. 2021. PMID: 34751523. doi:10.1515/cclm-2021-0790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。